ArticleBMC medicine2020
Cost-effectiveness of introducing national seasonal influenza vaccination for adults aged 60 years and above in mainland China: a modelling analysis.
Article in BMC medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Use of Health State Utility Values in Cost-Utility Analyses of Selected Infectious Diseases in Aging Populations: A Systematic Review and Critical Appraisal.PharmacoEconomics - open · 2026Pooled it
- Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022.PLoS medicine · 2024Pooled it
- Influenza-associated disease burden in mainland China: a systematic review and meta-analysis.Scientific reports · 2021Pooled it
- Article
- Uptake, willingness, and practices toward seasonal influenza vaccination among healthcare workers in China: a cross-sectional study.Frontiers in public health · 2026Article
- Cost-effectiveness and public health impact of influenza vaccination strategies for Chinese patients with rheumatoid arthritis.Human vaccines & immunotherapeutics · 2025Article
- Parents' preference for the inclusion of pediatric vaccines in the Chinese National Immunization Program: A discrete choice experiment.Human vaccines & immunotherapeutics · 2025Article
- Article
- Article
- Review
- A thematic analysis of flu vaccine hesitance in ethnically minoritised communities in Liverpool.PloS one · 2025Article
- Resource utilisation and cost of hospitalisation with community-acquired pneumonia among older adults in India, 2018-2020.BMJ public health · 2025Article
- The impact of the COVID-19 pandemic and the free vaccination policy on seasonal influenza vaccination uptake among older adults in Ningbo, Eastern China.Human vaccines & immunotherapeutics · 2024Article
- Cost-Effectiveness Analysis of Vaccination Compliance Strategies Using a Novel Hybrid Model for Influenza Vaccination.China CDC weekly · 2024Article
- Public Preference and Priorities for Including Vaccines in China's National Immunization Program: Discrete Choice Experiment.JMIR public health and surveillance · 2024Article
- Vaccine uptake, associated factors and reasons for vaccination status among the South African elderly; findings and next steps.PloS one · 2024Article
- Influenza vaccination for heart failure patients: a cost-effectiveness analysis from the perspective of Chinese healthcare system.Frontiers in public health · 2024Article
- Cost-effectiveness of seasonal influenza vaccination of children in China: a modeling analysis.Infectious diseases of poverty · 2023Article
- Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study.BMJ global health · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundChina has an aging population with an increasing number of adults aged ≥ 60 years. Influenza causes a heavy disease burden in older adults, but can be alleviated by vaccination. We assessed the cost-effectiveness of a potential government-funded seasonal influenza vaccination program in older adults in China.
methodsWe characterized the health and economic impact of a fully funded influenza vaccination program for older adults using China-specific influenza disease burden, and related cost data, etc. Using a decision tree model, we calculated the incremental costs per quality-adjusted life year (QALY) gained of vaccination from the societal perspective, at a willingness-to-pay threshold equivalent to GDP per capita (US$8840). Moreover, we estimated the threshold vaccination costs, under which the fully funded vaccination program is cost-effective using GDP per capita as the willingness-to-pay threshold.
resultsCompared to current self-paid vaccination, a fully funded vaccination program is expected to prevent 19,812 (95% uncertainty interval, 7150-35,783) influenza-like-illness outpatient consultations per year, 9418 (3386-17,068) severe acute respiratory infection hospitalizations per year, and 8800 (5300-11,667) respiratory excess deaths due to influenza per year, and gain 70,212 (42,106-93,635) QALYs per year. Nationally, the incremental costs per QALY gained of the vaccination program is US$4832 (3460-8307), with a 98% probability of being cost-effective. The threshold vaccination cost is US$10.19 (6.08-13.65). However, variations exist between geographical regions, with Northeast and Central China having lower probabilities of cost-effectiveness.
conclusionsOur results support the implementation of a government fully funded older adult vaccination program in China. The regional analysis provides results across settings that may be relevant to other countries with similar disease burden and economic status, especially for low- and middle-income countries where such analysis is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.